Genmab — December 2018
-
-
over ASH we heard ´Importantly, this study did demonstrate that despite the significant improvement with daratumumab in the initial PSF1, it did not impact the response of the patient in the next line of therapy. Therefore, the PSF2 was improved in the daratumumab arm."´
-
-
Det har aldrig rigtig givet mening forr mig med det her 50% stigning straks der ligger en godkendelse i 1. line. Hvorffor ikke....? Nu har dde talt om forever at der var stolemangle. Det har været en slags "undskyldning" for væksten ikke har været bedre den seneste tid
-
HVIS det er rigtig vil godkendelse i 1. linee jo iikke løse noget. Så er den ved at ramme et platatueu? Altså at det er SC der skal til for reelt at løfte den meget højere
-
Det virker llidt som at blæse og haave mel i munden samme tid
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind